The purpose of this Notice is to clarify instructions in PAR-24-272 “Clinical and Translational Science Award (UM1 Clinical Trial Optional)” about applications proposing to conduct research with Human Subjects and/or to conduct a clinical trial within the proposed project period.

Section IV. Application and Submission Information
2. Content and Form of Application Submission
PHS Human Subjects and Clinical Trials Information

Currently Reads:

PHS Human Subjects and Clinical Trials Information

When involving human subjects research, clinical research, and/or NIH-defined clinical trials (and when applicable, clinical trials research experience) follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the How to Apply – Application Guide, with the following additional instructions:

If you answered “Yes” to the question “Are Human Subjects Involved?” on the R&R Other Project Information form, you

Click this link to continue reading the article on the source website.

The purpose of this notice is to inform potential applicants of NINDS’s scientific objectives, resources communicating scientific interests for Dissemination and Implementation Research in Health (R21 Clinical Trial Optional), PAR-25-143. Applicants are encouraged to contact the Scientific/Research contact to ensure that the aims of the proposed project are consistent with the NINDS mission.

Section I. Notice of Funding Opportunity Description – Information relevant to Specific Institutes/Centers

Additional language for NINDS:

National Institute of Neurological Disorders and Stroke (NINDS)

The National Institute of Neurological Disorders and Stroke (NINDS) is interested in mission relevant applications. The NINDS supports dissemination and implementation research focused on identifying, monitoring, scaling-up, and/or testing strategies for overcoming environmental, social, community, structural, and healthcare system factors that lead to or are associated

Click this link to continue reading the article on the source website.

The purpose of this Notice is to extend the expiration date for PAR-24-289 “Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)” from September 06, 2025, to December 6, 2025. The last day applications will be accepted is December 5, 2025.

Currently, reads:

Application Due Date(s)

All applications are due by 5:00 PM local time of applicant organization.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Expiration Date: September 6, 2025

Modified to read:

Application Due Date(s)

All applications are due by 5:00 PM local time of applicant organization.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission

Click this link to continue reading the article on the source website.